Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | DNM1 | Q05193 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7072895 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL129696 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL197417 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL6385316 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL129402 | 1.00 | — | — | |
| SCHEMBL130979 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL6387311 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL49384 | 1.00 | — | — | |
| SCHEMBL131525 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL6387586 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240009230-A1 | PT(IV) CHEMOTHERAPEUTIC PRODRUG AND CONTROLLED RELEASE THEREOF FOR TREATMENT OF TUMORS | PEKING UNIVERSITY (CN) | 2024-01-11 | — | — | US | claimed |
| EP-4253392-A1 | PT(IV) CHEMOTHERAPEUTIC PRODRUG AND CONTROLLED RELEASE THEREOF FOR TREATMENT OF TUMORS | Peking University (CN) | 2023-10-04 | — | — | EP | claimed |
| CN-116635396-A | Pt (IV) chemotherapeutic prodrugs and their controlled release for treating tumors | 北京大学 | 2023-08-22 | — | — | CN | claimed |
| US-20240092810-A1 | COMPOSITIONS FOR EXTREME ULTRAVIOLET LITHOGRAPHY AND RELATED METHODS | ENTEGRIS, INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2024049919-A1 | COMPOSITIONS FOR EXTREME ULTRAVIOLET LITHOGRAPHY AND RELATED METHODS | ENTEGRIS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20240009230-A1 | PT(IV) CHEMOTHERAPEUTIC PRODRUG AND CONTROLLED RELEASE THEREOF FOR TREATMENT OF TUMORS | PEKING UNIVERSITY (CN) | 2024-01-11 | — | — | US | disclosed |
| EP-4253392-A1 | PT(IV) CHEMOTHERAPEUTIC PRODRUG AND CONTROLLED RELEASE THEREOF FOR TREATMENT OF TUMORS | Peking University (CN) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023176796-A1 | SCAR FORMATION INHIBITOR, FIBROBLAST PROLIFERATION INHIBITOR, AND METHOD FOR PRODUCING NANOPARTICLES | 国立大学法人東北大学 | 2023-09-21 | — | — | WO | disclosed |
| CN-116635396-A | Pt (IV) chemotherapeutic prodrugs and their controlled release for treating tumors | 北京大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-116099978-A | Three-component amine method cold box binder | 济南圣泉集团股份有限公司 | 2023-05-12 | — | — | CN | disclosed |
| EP-3689891-B1 | COBALT COMPLEX, PRODUCTION METHOD THEREFOR, AND CATALYST FOR HYDROSILYLATION REACTION | UNIV KYUSHU NAT UNIV CORP (JP) | 2023-03-01 | — | — | EP | disclosed |
| US-5064962-A | DIAMINOTHIOPHENES | BASF AKTIENGESELLSCHAFT (DE) | 1991-11-12 | — | — | US | disclosed |
| EP-0433879-A2 | Aminothiazoles | BASF Aktiengesellschaft (DE) | 1991-06-26 | — | — | EP | disclosed |
| EP-0421441-A2 | Pantothenic acid derivatives | FUJIREBIO INC. (JP) | 1991-04-10 | — | — | EP | disclosed |
| EP-0384314-A2 | Diaminothiophenes | BASF Aktiengesellschaft (DE) | 1990-08-29 | — | — | EP | disclosed |
| EP-0159913-B1 | SILVER HALIDE PHOTOGRAPHIC LIGHT SENSITIVE MATERIAL | KONICA CORPORATION (JP) | 1988-09-14 | — | — | EP | disclosed |
| EP-0094804-B1 | GLUCOSAMINYL MURAMYL PEPTIDE DERIVATIVES | Dainippon Pharmaceutical Co., Ltd. (JP) | 1985-11-13 | — | — | EP | disclosed |
| EP-0159913-A1 | Silver halide photographic light sensitive material | KONICA CORPORATION (JP) | 1985-10-30 | — | — | EP | disclosed |
| US-4545932-A | NONSPECIFIC RESISTANCE TO MICROBIAL INFECTIONS, IMMUNOSTIMULANTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1985-10-08 | — | — | US | disclosed |
| EP-0094804-A1 | Glucosaminyl muramyl peptide derivatives | Dainippon Pharmaceutical Co., Ltd. (JP) | 1983-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092810-A1 | COMPOSITIONS FOR EXTREME ULTRAVIOLET LITHOGRAPHY AND RELATED METHODS | ALG3, VCL, ETV6 | TSHR 3896/4885THRB 3319/4885DNM1 1449/4885 |
| US-20240009230-A1 | PT(IV) CHEMOTHERAPEUTIC PRODRUG AND CONTROLLED RELEASE THEREOF FOR TREATMENT OF TUMORS | TK1, TYMP, KIT | TSHR 833/4885THRB 941/4885DNM1 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.